Drugs / Cipatinib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01301911 | Jan 2011 → Nov 2012 | breast cancer | Jiangsu HengRui Medicine Co., Ltd. | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cipatinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01301911 ↗ |
| Action | Inhibit | “tyrosine kinase inhibitor targeting both HER-1 and HER-2 receptors” NCT01301911 ↗ |
| Modality | Small molecule | “Cipatinib is an oral tyrosine kinase inhibitor” NCT01301911 ↗ |
| Route | Oral | “p.o. once daily” NCT01301911 ↗ |